May 11, 2026 01:21PM
Feb 27, 2026 06:20AM
Jan 13, 2026 12:19PM
Nov 7, 2025 08:50AM
Nov 7, 2025 08:42AM
Apr 24, 2025 02:14AM
Jul 26, 2024 06:46AM Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases
Jun 10, 2024 04:54PM
Apr 24, 2024 01:00AM
Feb 13, 2024 04:08PM
Aug 16, 2023 03:32PM
Jul 21, 2023 08:52AM
Jul 21, 2023 07:52AM
Jul 19, 2023 12:42PM Ipsen announces European Commission decision on palovarotene for the treatment of FOP
Jun 28, 2023 08:00PM
Jun 14, 2023 04:35PM
Jun 14, 2023 02:21PM
Jun 13, 2023 01:10PM
Jun 12, 2023 01:00AM
May 26, 2023 08:20AM
Apr 27, 2023 01:00AM Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Mar 16, 2023 02:02PM
Mar 2, 2023 02:13PM
Feb 9, 2023 01:00AM
Jan 27, 2023 01:00AM
Jan 20, 2023 10:00AM
Jan 9, 2023 04:52AM
Jan 9, 2023 01:00AM Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
Dec 23, 2022 05:00PM
Nov 9, 2022 06:57AM
Nov 9, 2022 01:01AM
Oct 27, 2022 12:57AM
Oct 25, 2022 10:20AM
Aug 12, 2022 11:35AM
Aug 3, 2022 01:00AM Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
Aug 1, 2022 01:00AM
Jul 28, 2022 12:57AM
Jun 29, 2022 01:00AM
Jun 27, 2022 01:01AM
Jun 27, 2022 01:00AM
May 3, 2022 01:00AM
Mar 25, 2022 08:44AM Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
Mar 16, 2022 02:30AM
Feb 11, 2022 01:00AM
Dec 17, 2021 01:00AM
Oct 21, 2021 01:36AM
Aug 13, 2021 01:00AM
Jul 29, 2021 01:00AM
Jun 28, 2021 06:17AM Exelixis (EXEL) and Ipsen Report Mixed Results with Cabozantinib in Combination with Immune Checkpoint Inhibitor in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Live
Jun 28, 2021 01:00AM

322,241 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All